增加心血管药物的社会效益
Marcello Tonelli1, Sharon Straus2
1Department of Medicine, University of Calgary, Canada (M.T.).
Circulation
|November 21, 2022
概括
新的慢性疾病治疗方法如SGLT2抑制剂和GLP-1激动剂提供了更好的结果. 这本书概述了最大限度地提高社会效益,确保价值,并促进所有患者的公平获取的五个原则.
科学领域:
- 药理学和治疗学
- 健康经济学
- 公共卫生政策
背景情况:
- 目前可用于治疗非传染性慢性疾病的几种创新疗法,包括-葡萄糖携带体-2 抑制剂 (SGLT2i),葡萄糖样1 激动剂 (GLP-1a),血管激素受体-尼普利辛抑制剂 (ARNI) 和芬瑞.
- 这些新药在与现有治疗方案相结合时,显示出更好的临床相关结果,并扩大了它们的使用指示.
- 目前的药物管理制度的复杂性和成本在确保社会从这些进步中获得最大利益方面构成重大挑战.
研究的目的:
- 应对创新性非传染性疾病治疗的最大社会效益的挑战.
- 提出一个基于五个核心原则的框架来实现最佳的新疗法.
- 为高收入国家的利益相关者提供指导,为低收入和中等收入国家提供广泛适用的原则.
主要方法:
- 这是一本以讨论为基础的小册子,
- 专注于-葡萄糖携带体-2 抑制剂 (SGLT2i) 作为案例研究.
- 适应性框架适用于其他健康产品,如ARNI,finerenone和未来的创新.
主要成果:
- 确定了五个关键原则:最大限度地利用,最大限度地减少伤害,最大限度地利用,提高价值,确保公平获取.
- 强调这些原则在SGLT2i以外的其他新型NCD治疗中具有广泛的适用性.
- 突出了不同经济环境的利益相关者,包括高收入和低收入至中等收入国家.
结论:
- 基于原则的战略方法对于实现创新的非传染性疾病治疗的全部社会价值至关重要.
- 优化SGLT2i,GLP-1a,ARNI和finerenone等新药的使用和获取需要仔细考虑经济和公平因素.
- 提出的五项原则为应对全球医疗保健系统中先进疗法的复杂性提供了坚实的框架.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
01:17Exercise and Cardiac Output
1.2K
Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be...
Sustained exercise increases the muscles' oxygen demand, which can be...
1.2K
01:26Atherosclerosis III: Management
19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
01:20Exercise and Cardiovascular Response
1.0K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
1.0K
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
483
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
483